ARS Pharmaceuticals Q1 revenue beats estimates on neffy sales growth

ARS Pharmaceuticals

15/05/2026 11:12

Overview

U.S. biopharma firm's Q1 revenue rose yr/yr, beating analyst expectations

Company's Q1 net loss widened as operating expenses rose on sales force expansion, marketing

Sales force expansion to 148 representatives completed; CVS Caremark formulary proposal in final approval stages

Outlook

Company expects prescription renewals to drive market share growth in H2 2026

ARS Pharma anticipates majority of Medicaid state plans to cover neffy by early 2027

Interim data from Phase 2b CSU trial expected in Q4 2026

Result Drivers

NEFFY SALES GROWTH - Q1 revenue driven by U.S. net product sales of neffy, supported by increased healthcare provider adoption and repeat prescribing

SALES FORCE EXPANSION - Expansion from 106 to 148 sales representatives increased engagement with high-prescribing allergists

BROADENING ACCESS - Progress in payor coverage, including Medicaid expansion and a pending CVS Caremark formulary proposal, aimed at increasing patient access

Company press release: ID:nGNX3qxbSB

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$22.70 mln
$22.23 mln (6 Analysts)
Q1 EPS
-$0.61
Q1 Net Income
-$60.62 mln
Q1 Cash & Investments
$201 mln
Q1 Operating Expenses
$82.83 mln
Q1 Operating Income
-$60.15 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for ARS Pharmaceuticals Inc is $28.00, about 252.6% above its May 14 closing price of $7.94

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)